Shortened BDLC Regimen Not Noninferior for Drug-Resistant TB

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 22, 2025.

via HealthDay

TUESDAY, July 22, 2025 -- For preextensively drug resistant tuberculosis (TB), a shortened bedaquiline, delamanid, linezolid, and clofazimine (BDLC) regimen is not noninferior to longer standard of care, according to a study published online July 16 in The Lancet Respiratory Medicine.

Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted an open-label, noninferiority, randomized phase 3 trial in 10 hospitals involving participants aged 15 years or older who had pulmonary TB with resistance to rifampicin and fluoroquinolones. Participants were randomly assigned to receive BDLC or individualized World Health Organization-recommended longer standard of care (control) in a 2:1 ratio (219 and 105 individuals, respectively). BDLC was administered for nine months for extensive disease and for six months for limited disease.

The researchers found that at week 73, favorable outcome was reached by 87 and 89 percent of the modified intention-to-treat population in the BDLC and control groups, respectively (adjusted risk difference, 0.2 percent; Pnoninferiority = 0.0051) and by 88 and 93 percent of the per-protocol population (adjusted risk difference, −3.5 percent; Pnoninferiority = 0.037). Overall noninferiority was not demonstrated. At least one grade 3 or higher adverse event occurred in 68 and 73 percent of participants in the BDLC and control groups, respectively, with eight and two all-cause deaths occurring by week 73 (4 and 2 percent, respectively).

"This shorter regimen is not a surefire cure for everyone," co-senior author Carole D. Mitnick, Sc.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, said in a statement. "The big takeaway is that we might need a more tailored approach to treatment of this kind of resistant TB."

One author disclosed ties to Janssen Pharmaceuticals.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-23 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords